March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Analysis Of Photoreceptor Abnormality In Gucy2d E837D/R838S Transgenic Pigs
Author Affiliations & Notes
  • Corinne Kostic
    Gene Therapy & Stem Cell Biol, Jules-Gonin Eye Hosp, Univ Lausanne, Lausanne, Switzerland
  • Tim King
    Division of Developmental Biology, The Roslin Institute, University of Edinburgh, Scotland, United Kingdom
  • Crippa Sylvain
    Gene Therapy & Stem Cell Biol, Jules-Gonin Eye Hosp, Univ Lausanne, Lausanne, Switzerland
  • Stéphanie Philippe
    NewVectys, Paris, France
  • Simon Lillico
    Division of Developmental Biology, The Roslin Institute, University of Edinburgh, Scotland, United Kingdom
  • Chamsy Sarkis
    NewVectys, Paris, France
  • Jacques Mallet
    Team of Biotherapy and Biotechnology, CRICM, Paris, France
  • Yvan Arsenijevic
    Gene Therapy & Stem Cell Biol, Jules-Gonin Eye Hosp, Univ Lausanne, Lausanne, Switzerland
  • Bruce Whitelaw
    Division of Developmental Biology, The Roslin Institute, University of Edinburgh, Scotland, United Kingdom
  • Footnotes
    Commercial Relationships  Corinne Kostic, FAA & Univ Lausanne, Switzerland (P); Tim King, None; Crippa Sylvain, None; Stéphanie Philippe, NewVectys, Paris, France (E); Simon Lillico, Univ Edinburgh, UK (P); Chamsy Sarkis, CNRS & NewVectys, France (P), NewVectys, Paris, France (E); Jacques Mallet, None; Yvan Arsenijevic, FAA & Univ Lausanne, Switzerland (P); Bruce Whitelaw, Univ Edinburgh, UK (P)
  • Footnotes
    Support  FP6 INTEGRA 029025-2, Retina France
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 6462. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Corinne Kostic, Tim King, Crippa Sylvain, Stéphanie Philippe, Simon Lillico, Chamsy Sarkis, Jacques Mallet, Yvan Arsenijevic, Bruce Whitelaw; Analysis Of Photoreceptor Abnormality In Gucy2d E837D/R838S Transgenic Pigs. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6462.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : We generated genetically engineered pigs expressing the human dominant GUCY2DE837D/R838S allele to modelize cone dystrophy. After a functional follow-up showing reduced photopic ERG responses (ARVO 2011), we analyzed the eyes by immunohistochemistry and revealed retinal modifications in the transgenic group.

Methods: : Lentiviral vectors encoding the human double mutant GUCY2DE837D/R838S cDNA under the control of a portion of the pig arrestin-3 promoter (Arr3) were produced and used for lentiviral-mediated transgenesis in pigs. Animals were regularly submitted to behavioral and functional investigations and were sacrificed at 4, 7, 15 and 18 months of age for histological and RT-PCR analyses. Retinal markers were used to evaluate the retinal status of eleven transgenic pigs and 6 non-transgenic controls. The expression of the mutant cDNA was also assayed by RT-PCR.

Results: : A significant increase in the number of displaced nuclei in the outersegment layer is observed in transgenic animals compared to control animals independently of their age. Part of these nuclei originate from cones as demonstrated by colocalization with cone markers. No significant change in the ONL thickness (central and peripheral retina) was measured between 4 and 18 months of age, showing a slow progression of the disease in the transgenic pigs within this time-frame.

Conclusions: : Arr3-GUCY2DE837D/R838S pigs show signs of retinal abnormality with slow progression which parallels the loss of photopic function. Further characterization of this model should help to elucidate the molecular mechanisms underlying the disease evolution.

Keywords: retinal degenerations: cell biology • photoreceptors • genetics 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×